International Ophthalmology

, Volume 30, Issue 1, pp 15–22 | Cite as

Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results

  • Julia Beutel
  • Focke Ziemssen
  • Matthias Lüke
  • Michael Partsch
  • Karl-Ulrich Bartz-Schmidt
  • The Bevacizumab Study Group
  • Faik Gelisken
Original Paper

Abstract

Purpose To report on the anatomic and visual acuity response after intravitreal bevacizumab injection in patients with macular edema due to non-ischemic central retinal vein occlusion (CRVO). Methods In a retrospective study, 21 consecutive patients (21 eyes) with non-ischemic CRVO underwent, on average, 3.7 intravitreal bevacizumab injections (1.25 mg). Ophthalmic examination included best corrected visual acuity (BCVA) and central retinal thickness (CRT) at baseline and follow-up visits. Fluorescein angiography was performed at baseline and at follow-up visits if needed. Primary outcomes were change of BCVA and CRT. Results The follow-up period for all of the included patients was 12 months. The mean BCVA was unchanged at the 12-month examination (baseline: 20/160; 12 months: 20/160) (P = 0.771). The mean CRT decreased from 780 μm (standard deviation [SD] ± 324 μm) at the baseline to a mean of 462 μm (SD ± 248 μm) at 12 months (P < 0.05). Conclusion Intravitreal bevacizumab resulted in a significant decrease in CRT without significant improvement of visual acuity in patients with non-ischemic CRVO after a follow-up of 12 months.

Keywords

Anti-VEGF Bevacizumab Central retinal vein occlusion Macular edema Treatment 

References

  1. 1.
    The Central Vein Occlusion Study Group M Report (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 102:1425–1433Google Scholar
  2. 2.
    Mohamed Q, McIntosh RL, Saw SM et al (2007) Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114:507–519. doi: 10.1016/j.ophtha.2006.11.011, 524CrossRefPubMedGoogle Scholar
  3. 3.
    Costa RA, Jorge R, Calucci D et al (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149. doi: 10.1097/IAE.0b013e31802eff83 CrossRefPubMedGoogle Scholar
  4. 4.
    Hsu J, Kaiser RS, Sivalingam A et al (2007) Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina 27:1013–1019CrossRefPubMedGoogle Scholar
  5. 5.
    Iturralde D, Spaide RF, Meyerle CB et al (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284. doi: 10.1097/00006982-200603000-00005 CrossRefPubMedGoogle Scholar
  6. 6.
    Pai SA, Shetty R, Vijayan PB et al (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606. doi: 10.1016/j.ajo.2006.12.037 CrossRefPubMedGoogle Scholar
  7. 7.
    Priglinger SG, Wolf AH, Kreutzer TC et al (2007) Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27:1004–1012CrossRefPubMedGoogle Scholar
  8. 8.
    Schaal KB, Höh AE, Scheuerle A et al (2007) Bevacizumab zur Therapie des Makulaödems infolge venöser retinaler Gefäßverschlüsse. Ophthalmologe 104:285–289. doi: 10.1007/s00347-007-1509-x CrossRefPubMedGoogle Scholar
  9. 9.
    Spandau UH, Ihloff AK, Jonas JB (2006) Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 84:555–556. doi: 10.1111/j.1600-0420.2006.00740.x CrossRefPubMedGoogle Scholar
  10. 10.
    Stahl A, Agostini H, Hansen LL et al (2007) Bevacizumab in retinal vein occlusion—results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245:1429–1436. doi: 10.1007/s00417-007-0569-6 CrossRefPubMedGoogle Scholar
  11. 11.
    Matsumoto Y, Freund KB, Peiretti E et al (2007) Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 27:426–431. doi: 10.1097/IAE.0b013e31804a7af2 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Julia Beutel
    • 1
  • Focke Ziemssen
    • 2
  • Matthias Lüke
    • 1
  • Michael Partsch
    • 2
  • Karl-Ulrich Bartz-Schmidt
    • 2
  • The Bevacizumab Study Group
    • 3
  • Faik Gelisken
    • 2
  1. 1.Eye HospitalUniversity Clinic of Schleswig-HolsteinLübeckGermany
  2. 2.University Eye Hospital at the Centre for OphthalmologyEberhard-Karls University of TuebingenTuebingenGermany
  3. 3.TuebingenGermany

Personalised recommendations